Efficacy of Intra-vitreal Bevacizumab for Resolution of Macular Edema Secondary to Central Retinal Vein Occlusion
Purpose: To determine the efficacy of intravitreal injection of Bevacizumab in
resolution of macular edema in patients of central retinal vein occlusion.
Material and Methods: It was a descriptive case series, conducted at Institute
of Ophthalmology unit III, Mayo Hospital Lahore and Bahawal – Victoria Hospital
Bahawalpur simultaneously. A total of 60 cases were selected though purposive
sampling for this study. Diagnosis was ascertained on fundus fluorescein
angiography. Pre and post injection macular edema was measured on optical
coherence tomography on the day of drug administration and thirty days after it.
Results: Mean macular thickness before treatment was 663.10 ± 109.76
microns and after treatment mean thickness was 453.06 ± 106.09 microns which
was a significant (p = 0.0000001) finding. Majority (75%) of patients achieved a
reduction of ≥ 200 microns in their retinal thickness after treatment. Whereas in
the remaining 15 (25%) patients reduction in retinal thickness was < 200
microns. These findings were independent of gender bias.
Conclusion: Intravitreal injection of Bevacizumab is effective in the resolution of
macular edema in the patients of central retinal vein occlusion.
Key words: Central retinal vein occlusion, macular edema, Bevacizumab.